Floatz logo

Buparlisib

Advanced or Metastatic Breast Cancer

Novartis PharmaceuticalsSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

891 Active assets in the Advanced or Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Buparlisib is also rated in:

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
54 / 100
View asset →
urothelial carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →